Boston biotech seed funding drops 40% as investors favor later-stage firms

Boston remains the world’s largest biotech hub, but early‑stage startups are feeling a sharp squeeze in capital. The average seed round for a pre‑clinical company in Massachusetts fell to $4.65 million in the first half of 2026, a 40% decline from the same period a year earlier.

Industry data from MassBio shows the drop is part of a longer trend, with the 2026 average now only a third of the $11.1 million seen in 2022. A J.P. Morgan report confirms the slowdown is global, noting $4.8 billion raised in seed and Series A deals in the first half of 2026 – the lowest level in five years and less than half of the $11.1 billion raised in the same period in 2025.

Analysts say investors are gravitating toward companies that already have solid data packages and clearer near‑term value inflection points, leaving early‑stage biotechs to compete for a much smaller pool of funding.